$ASX

ASE (ASX) Q2 2026 Earnings Call Transcript

ASE Technology Holding Co. reported Q2 2026 revenue of TWD 191.1B (+10% sequential, +27% YoY) and net income of TWD 21.1B (+49% sequential, +180% YoY). ATM revenue was TWD 126.1B, gross margin 27.3%. Management raised annual CapEx guidance to $10.5B and guided Q3 revenue +21% to +22% sequential.

Original reporting
Published Aug 8, 2026, 2:15 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 8, 2026, 2:39 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ASE (ASX) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$ASXBullishMed
01

Why it matters

Traders can update expectations for segment growth (ATM and EMS), margin progression (ATM gross margin), and cash flow risk (CapEx exceeding EBITDA) based on the disclosed guidance and capital plan.

02

Market read

The call provides concrete forward guidance and a capital intensity update tied to AI packaging demand, which can drive repricing of growth and margin expectations.

03

What to watch

EMS margin is declining (2.4% operating margin, down 0.6pp) and Q3 EMS growth is attributed to memory component price hikes, which may not translate into durable end-demand strength.

Relevance 8/10Novelty 8/10Timing: post-market? (call transcript dated Jul. 30, 2026, published Aug. 8)

Background

ASE Technology Holding discussed Q2 2026 results and framed the business around an AI-driven shift requiring more complex advanced packaging and testing capacity.

Company-level read

Ticker impact

$ASXBullishMedium confidence
Context

ASE guided higher annual CapEx to $10.5B, raised ATM growth to 35%, and expects Q3 revenue growth of 21% to 22%.

Expected impact

Near-term bias positive on guidance credibility, but investors may discount for cash flow pressure from elevated CapEx versus EBITDA.

Evidence & confidence

Management disclosed multiple forward-looking datapoints: annual CapEx increase, Q3 consolidated and segment growth ranges, ATM gross margin range, and a stated risk of negative cash flow due to CapEx exceeding EBITDA.

Market effects

Supports the OSAT/advanced packaging theme that AI compute is constrained by packaging and testing capacity, not just wafer supply.

Highlights Taiwan and North America manufacturing expansion as a key execution lever for AI packaging demand.

Reinforces global supply chain bottlenecks around LEAP/advanced packaging equipment and capacity buildouts.

Counterpoint

The company’s margin ceiling may be exceeded only temporarily, while cash flow remains pressured as CapEx outpaces EBITDA for an extended period.

Key entities

  • ASE Technology Holding Co., Ltd.

    Discussed Q2 results and provided Q3 and full-year guidance for ATM, EMS, margins, and a higher annual CapEx plan.

  • Tien Wu

    COO who emphasized hardware infrastructure as the new bottleneck and provided timing for automated packaging line production.

  • Joseph Tung

    CFO who discussed structural gross margin ceiling expectations and cash flow risk tied to elevated CapEx.

Related articles

$ASXMedAI 8/10

Taiwan's ASE Tech raises 2026 capex by $2 billion on strong demand

ASE Technology Holding said it will raise 2024 capex by $2 billion to about $10.5 billion due to strong demand. The increase is split between $1 billion for facilities and $1 billion for equipment. It expects LEAP revenue to track ahead of 2026 guidance of $3.5 billion and aims to double LEAP revenue in 2027. Q2 revenue rose to T$191.06 billion and net income to T$21.068 billion.

$ASXMed

ASE Technology Q2 Earnings Call Highlights

ASE Technology (NYSE:ASX) reported Q2 EMS revenue of TWD 65.8B, up 6% sequentially and 12% YoY, but gross margin fell to 8.9% and operating margin to 2.4% due to product mix and higher component costs. Q3 guidance calls for 21% to 22% NTD revenue growth and 11.5% to 12.5% operating margin. Capex rises toward 2026.

$ASXMed

Larvotto digs in as Hammer takeover battle heats up

Larvotto Resources defended its June scheme to acquire Hammer Metals after Austral Resources made a competing indicative all-scrip proposal. Larvotto said Austral’s offer is non-binding and would require due diligence and deal documents. Hammer shareholders would get 1 Larvotto share for 22 Hammer shares, valuing it at 5.6c. Glencore backed Larvotto with $15m and a 7-year gold concentrate offtake.

$ASXMedAI 8/10

ASX Admits Misleading Conduct On CHESS Project, To Pay A$20.5 Mln Penalty In Settlement With ASIC

ASX Limited said it has settled ASIC proceedings over misleading statements made in 2022 about the CHESS replacement project. ASX admitted contravening ASIC Act provisions, including a “progressing well” representation. The settlement requires a A$20.5 million penalty plus A$3 million toward ASIC legal costs, subject to Federal Court approval, ending the trial.

$ASXMed

ASX to pay $20.5m penalty for misleading market

ASX Ltd will pay a $20.5m penalty and $3m in ASIC legal costs to settle claims it made a misleading statement about its CHESS clearing and settlement upgrade, according to ASIC. ASIC says ASX told investors in Feb 2022 the project was “progressing well,” then later flagged a likely delay. ASX scrapped the project and wrote off $245m–$255m; the settlement avoids trial pending Federal Court approval.